Poor
Not Label Aligned
Patient Risk:
Medium
Summary
Many extracted claims are unsupported by the provided prescribing information and several are potentially misleading generalizations (e.g., other dosage forms and generic/patent/bioequivalence statements). Additionally, major label areas were not evaluated (e.g., contraindications, boxed warnings, and use in specific populations), so label-adherence cannot be assured.
Category Scores
Accurate Statements
Mesalamine is also known as 5-aminosalicylic acid (5-ASA).
Section 11: DESCRIPTION (mesalamine also known as 5-aminosalicylic acid (5-ASA)).
Mesalamine is formulated in suppositories.
Section 3: DOSAGE FORMS AND STRENGTHS (Mesalamine Rectal Suppository...).
More serious side effects of mesalamine can involve kidney problems.
Section 6: ADVERSE REACTIONS lists Renal Impairment as a serious/clinically significant adverse reaction.
More serious side effects of mesalamine can involve liver issues.
Section 6: ADVERSE REACTIONS lists Hepatic Failure as a serious/clinically significant adverse reaction.
Unsupported Statements
Mesalamine is available in generic forms.
No support in the provided label sections.
Mesalamine is the active ingredient in drugs used to treat ulcerative colitis, proctitis, and proctosigmoiditis.
Provided label indication is only for ulcerative proctitis; other disease entities are not supported by the provided label excerpt.
The availability of generic mesalamine depends on patent expirations for branded versions.
No support in the provided label sections.
Generic entry for branded mesalamine products can be affected by patent challenges.
No support in the provided label sections.
Mesalamine is formulated in delayed-release tablets.
The provided label section describes only a mesalamine rectal suppository.
Mesalamine is formulated in extended-release capsules.
The provided label section describes only a mesalamine rectal suppository.
Mesalamine is formulated in enemas.
No enema dosage form described in the provided label sections.
Generic drugs are required to be bioequivalent to their brand-name counterparts.
No support in the provided label sections.
Bioequivalence requires the same active ingredient, dosage form, strength, and route of administration.
No support in the provided label sections.
Mesalamine brand names include Apriso.
No support in the provided label sections.
Contradictions
Low
AI Statement
Mesalamine is formulated in delayed-release tablets.
Label Reference
Section 3: DOSAGE FORMS AND STRENGTHS (only Mesalamine Rectal Suppository described in provided excerpt).
Low
AI Statement
Mesalamine is formulated in extended-release capsules.
Label Reference
Section 3: DOSAGE FORMS AND STRENGTHS (only Mesalamine Rectal Suppository described in provided excerpt).
Low
AI Statement
Mesalamine is formulated in enemas.
Label Reference
Section 3: DOSAGE FORMS AND STRENGTHS (only Mesalamine Rectal Suppository described in provided excerpt).
Important Omissions
Evaluation did not cover contraindications (Section 4), boxed warnings (if any), or key use-in-populations sections (e.g., pregnancy/lactation, pediatric use).
Importance:
High
Safety Assessment
Potential Patient Risk:
Medium
Several claims are unsupported by the provided label excerpt and include potentially misleading generalizations (e.g., other dosage forms, generic/patent/bioequivalence information, and brand-name equivalence). Major safety-critical label areas were not evaluated, preventing confirmation that safety messaging is label-adherent.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Label Aligned
Primary Issue
Multiple extracted claims are absent from the provided prescribing information and the audit did not evaluate key safety sections (contraindications/boxed warnings/specific populations).
Suggested Improvement
Restrict claims to information explicitly present in the provided label sections (especially Section 1 indication, Section 3 dosage forms, Section 6 adverse reactions). Add evaluation coverage for Section 4 (contraindications), boxed warning section (if present), and specific populations (pregnancy/lactation, pediatric use) before concluding overall label alignment.